Abcam to acquire BioVision for $340m
With BioVision’s acquisition Abcam plc complements its portfolio of research tools to support research, diagnostics, and drug discovery, particularly...
Visus Therapeutics cashes in €20m from LSP
Ophthalmic therapies spcialist Visus Therapeutics closed a $20m preferred stock financing, led by LSP from its LSP 6 fund, along with participation...
Boehringer Ingelheim: Takeover in immunooncology
Abexxa focusses on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human...
Bayer takes over Vividion
The acquisition strengthens Bayer's oncology and immunology pipeline and secures a revolutionary screening technology for small molecule drugs that...
Unilever licences Arzeda Inc.‘s enzyme technology
According to an analysis from Nova Institute (Cologne), production of chemicals including laundry products 85% (or 450 millon tonnes annually) of the...
NeuVasQ Biotechnologies bags €20m in Series A financing
Brussels-Basel VC investor Newton Biocapital led the financing round with a €10m contribution from its Newton Biocapital I fund. Another €10m...
Rheincell set to be acquired by Catalent
Under the agreement, Catalent will acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent...